RhumbLine Advisers’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.08M | Sell |
103,605
-6,162
| -6% | -$184K | ﹤0.01% | 1639 |
|
|
2025
Q4 | $4.19M | Sell |
109,767
-20,254
| -16% | -$659K | ﹤0.01% | 1487 |
|
|
2025
Q3 | $3.11M | Sell |
130,021
-1,938
| -1% | -$36.4K | ﹤0.01% | 1664 |
|
|
2025
Q2 | $1.95M | Buy |
131,959
+7,409
| +6% | +$123K | ﹤0.01% | 1898 |
|
|
2025
Q1 | $2.23M | Buy |
124,550
+3,302
| +3% | +$67K | ﹤0.01% | 1762 |
|
|
2024
Q4 | $2.11M | Buy |
121,248
+2,640
| +2% | +$46.7K | ﹤0.01% | 1849 |
|
|
2024
Q3 | $1.66M | Sell |
118,608
-7,052
| -6% | -$73.5K | ﹤0.01% | 2004 |
|
|
2024
Q2 | $1.03M | Buy |
125,660
+18,645
| +17% | +$126K | ﹤0.01% | 2223 |
|
|
2024
Q1 | $825K | Sell |
107,015
-1,221
| -1% | -$10.3K | ﹤0.01% | 2361 |
|
|
2023
Q4 | $973K | Sell |
108,236
-4,823
| -4% | -$35.1K | ﹤0.01% | 2265 |
|
|
2023
Q3 | $1.01M | Sell |
113,059
-384
| -0.3% | -$5.42K | ﹤0.01% | 2206 |
|
|
2023
Q2 | $1.74M | Buy |
113,443
+15,542
| +16% | +$283K | ﹤0.01% | 1982 |
|
|
2023
Q1 | $2.2M | Buy |
97,901
+265
| +0.3% | +$5.63K | ﹤0.01% | 1758 |
|
|
2022
Q4 | $2.05M | Buy |
97,636
+3,154
| +3% | +$66.8K | ﹤0.01% | 1771 |
|
|
2022
Q3 | $2.33M | Buy |
94,482
+6,926
| +8% | +$179K | ﹤0.01% | 1668 |
|
|
2022
Q2 | $2.12M | Sell |
87,556
-3,195
| -4% | -$80.4K | ﹤0.01% | 1736 |
|
|
2022
Q1 | $2.34M | Sell |
90,751
-7,019
| -7% | -$186K | ﹤0.01% | 1730 |
|
|
2021
Q4 | $3.04M | Buy |
97,770
+529
| +0.5% | +$14.9K | ﹤0.01% | 1649 |
|
|
2021
Q3 | $2.36M | Buy |
97,241
+3,009
| +3% | +$55.3K | ﹤0.01% | 1811 |
|
|
2021
Q2 | $1.38M | Buy |
94,232
+25,563
| +37% | +$504K | ﹤0.01% | 2108 |
|
|
2021
Q1 | $1.72M | Sell |
68,669
-2,409
| -3% | -$66.6K | ﹤0.01% | 1977 |
|
|
2020
Q4 | $1.94M | Buy |
71,078
+4,456
| +7% | +$104K | ﹤0.01% | 1859 |
|
|
2020
Q3 | $1.23M | Sell |
66,622
-5,132
| -7% | -$99.7K | ﹤0.01% | 1912 |
|
|
2020
Q2 | $1.46M | Sell |
71,754
-7,797
| -10% | -$124K | ﹤0.01% | 1889 |
|
|
2020
Q1 | $1.16M | Sell |
79,551
-2,008
| -2% | -$30.2K | ﹤0.01% | 1813 |
|
|
2019
Q4 | $1.16M | Buy |
81,559
+7,734
| +10% | +$98.8K | ﹤0.01% | 2011 |
|
|
2019
Q3 | $856K | Buy |
73,825
+1,157
| +2% | +$19.1K | ﹤0.01% | 2117 |
|
|
2019
Q2 | $1.46M | Buy |
72,668
+17,148
| +31% | +$339K | ﹤0.01% | 1902 |
|
|
2019
Q1 | $1.26M | Buy |
55,520
+273
| +0.5% | +$6.03K | ﹤0.01% | 1929 |
|
|
2018
Q4 | $1.25M | Buy |
55,247
+18,748
| +51% | +$466K | ﹤0.01% | 1902 |
|
|
2018
Q3 | $1.05M | Sell |
36,499
-2,350
| -6% | -$67.2K | ﹤0.01% | 1986 |
|
|
2018
Q2 | $1.06M | Sell |
38,849
-690
| -2% | -$18.4K | ﹤0.01% | 1985 |
|
|
2018
Q1 | $884K | Sell |
39,539
-1,145
| -3% | -$27.3K | ﹤0.01% | 1998 |
|
|
2017
Q4 | $857K | Sell |
40,684
-7,390
| -15% | -$169K | ﹤0.01% | 2014 |
|
|
2017
Q3 | $1.2M | Buy |
48,074
+620
| +1% | +$13.7K | ﹤0.01% | 1888 |
|
|
2017
Q2 | $920K | Buy |
47,454
+2,010
| +4% | +$36.5K | ﹤0.01% | 1987 |
|
|
2017
Q1 | $839K | Buy |
45,444
+2,218
| +5% | +$43.4K | ﹤0.01% | 2009 |
|
|
2016
Q4 | $818K | Sell |
43,226
-910
| -2% | -$18.6K | ﹤0.01% | 1964 |
|
|
2016
Q3 | $988K | Sell |
44,136
-100
| -0.2% | -$1.9K | ﹤0.01% | 1814 |
|
|
2016
Q2 | $788K | Buy |
44,236
+9,570
| +28% | +$155K | ﹤0.01% | 1934 |
|
|
2016
Q1 | $474K | Sell |
34,666
-45
| -0.1% | -$683 | ﹤0.01% | 2263 |
|
|
2015
Q4 | $670K | Buy |
34,711
+3,120
| +10% | +$62.3K | ﹤0.01% | 2065 |
|
|
2015
Q3 | $640K | Buy |
31,591
+713
| +2% | +$21.1K | ﹤0.01% | 2064 |
|
|
2015
Q2 | $1.02M | Buy |
30,878
+10,215
| +49% | +$280K | ﹤0.01% | 1854 |
|
|
2015
Q1 | $495K | Buy |
20,663
+3,000
| +17% | +$45.7K | ﹤0.01% | 2306 |
|
|
2014
Q4 | $216K | Buy |
17,663
+525
| +3% | +$5.43K | ﹤0.01% | 2770 |
|
|
2014
Q3 | $155K | Hold |
17,138
| – | – | ﹤0.01% | 2843 |
|
|
2014
Q2 | $201K | Buy |
+17,138
| New | +$232K | ﹤0.01% | 2831 |
|
Other funds holding TVTX
AC
PA
VCM
NAMI
RhumbLine Advisers's TVTX Position: Q1 2026 in Review
RhumbLine Advisers reduced its Travere Therapeutics (TVTX) stake by 5.6% in Q1 2026, selling an estimated $184K and leaving 103,605 shares worth $3.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1639.
RhumbLine Advisers first reported a position in TVTX in Q2 2014 and has held it in 48 quarters since. The position peaked at $4.19M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.
- RhumbLine Advisers held 103,605 shares of Travere Therapeutics worth $3.08M as of Q1 2026.
- RhumbLine Advisers sold 6,162 Travere Therapeutics shares in Q1 2026, an estimated $184K.
- Travere Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #1639 holding.
- RhumbLine Advisers first reported a position in Travere Therapeutics in Q2 2014 and has held it in 48 quarters since.
- RhumbLine Advisers's Travere Therapeutics position peaked at $4.19M in Q4 2025.
- 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.